Society ❯ Economics ❯ Market Behavior
Corporate Governance Public Offerings Shareholder Value Retail Investors Venture Capital Shareholder Advocacy
Plaintiffs allege MoonLake overstated sonelokimab’s Nanobody benefits in light of Phase 3 results that failed to show superior efficacy.